ViiV’s long-acting two-drug HIV regimen hits targets

25th July 2017 0

A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence.

More: ViiV’s long-acting two-drug HIV regimen hits targets
Source: News